Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Vbi Vaccines Inc CS (VBIV)

Vbi Vaccines Inc CS (VBIV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,739
  • Shares Outstanding, K 23,688
  • Annual Sales, $ 1,080 K
  • Annual Income, $ -113,300 K
  • 60-Month Beta 1.92
  • Price/Sales 0.84
  • Price/Cash Flow N/A
  • Price/Book 0.67
Trade VBIV with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -7.38
  • Most Recent Earnings $-0.38 on 11/14/23
  • Latest Earnings Date 04/01/24 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend 0.150 on 12/12/12
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 602.92% ( +77.78%)
  • Historical Volatility 52.96%
  • IV Percentile 83%
  • IV Rank 72.40%
  • IV High 813.09% on 11/13/23
  • IV Low 51.72% on 04/13/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 4
  • Volume Avg (30-Day) 171
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 4,712
  • Open Int (30-Day) 3,457

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.22
  • Number of Estimates 1
  • High Estimate -0.22
  • Low Estimate -0.22
  • Prior Year -2.40
  • Growth Rate Est. (year over year) +90.83%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5550 +8.58%
on 03/21/24
0.6360 -5.25%
on 03/11/24
+0.0423 (+7.55%)
since 02/28/24
3-Month
0.5300 +13.70%
on 02/14/24
0.7588 -20.59%
on 01/31/24
+0.0088 (+1.48%)
since 12/28/23
52-Week
0.4500 +33.91%
on 10/25/23
10.4700 -94.24%
on 03/30/23
-8.3824 (-93.29%)
since 03/28/23

Most Recent Stories

More News
Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination with PEG-IFNα for the Treatment of Chronic Hepatitis B

/PRNewswire/ -- Brii Biosciences Limited ("Brii Bio," "we," or the "Company," stock code: 2137.HK), a biotechnology company developing therapies to improve...

VBIV : 0.6026 (+3.90%)
Brii Biosciences Broadens its Leadership in Hepatitis B with a Portfolio Now Addressing Disease's Burdens from Prevention to Cure

/PRNewswire/ -- Brii Biosciences Limited ("Brii Bio," "we," or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve...

VBIV : 0.6026 (+3.90%)
Brii Biosciences Provides Latest Clinical Development and Corporate Updates

Company extends BRII-179 license to global rights and introduces preventive vaccine, PreHevbri® in Greater China and Asia Pacific markets New data from...

VIR : 10.13 (+0.30%)
VBIV : 0.6026 (+3.90%)
ANTX : 3.25 (+0.93%)
Brii Bio Announces New Data from Partners Underscoring Potential for HBV Functional Cure at EASLâ„¢ Congress 2023

/PRNewswire/ -- Brii Biosciences Limited ("Brii Bio", "we", or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve...

VIR : 10.13 (+0.30%)
VBIV : 0.6026 (+3.90%)
Absci Corporation (ABSI) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Absci Corporation (ABSI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ABSI : 5.68 (+2.53%)
VBIV : 0.6026 (+3.90%)
VBI Vaccines, Inc. (VBIV) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

VBI Vaccines, Inc. (VBIV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

VBIV : 0.6026 (+3.90%)
MIRM : 25.12 (unch)
VBI Vaccines Appoints Vaughn Himes to Board of Directors

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Vaughn B. Himes, Ph.D., Chief...

VBIV : 0.6026 (+3.90%)
VBI Vaccines (VBIV) Down 53% on Initiating Restructuring Plans

VBI Vaccines (VBIV) will focus on its HBV vaccine product and advancing its HBV immunotherapeutic candidate. It will also reduce the workforce by 30-35% and initiate a 1-for-30 reverse stock split.

CRSP : 68.16 (-2.85%)
VBIV : 0.6026 (+3.90%)
CERT : 17.88 (+1.48%)
EQRX : 2.34 (-2.09%)
VBI Vaccines Announces Increased Focus on Hepatitis B, Organizational Changes, and Reverse Stock Split

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced plans to focus the Company’s efforts...

VBIV : 0.6026 (+3.90%)
Brii Biosciences Provides Corporate Update and Reports Full-Year 2022 Financial Results

/PRNewswire/ -- Brii Biosciences Limited ("Brii Bio," "we," or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve...

VIR : 10.13 (+0.30%)
VBIV : 0.6026 (+3.90%)
ANTX : 3.25 (+0.93%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

VBI Vaccines Inc. is a biopharmaceutical company developing novel technologies to expand vaccine protection. The company's eVLP vaccine platform allows for the design of enveloped virus-like particle vaccines which closely mimic the target virus. Its lead eVLP asset is a prophylactic cytomegalovirus...

See More

Key Turning Points

3rd Resistance Point 0.6367
2nd Resistance Point 0.6249
1st Resistance Point 0.6137
Last Price 0.6026
1st Support Level 0.5907
2nd Support Level 0.5789
3rd Support Level 0.5677

See More

52-Week High 10.4700
Fibonacci 61.8% 6.6424
Fibonacci 50% 5.4600
Fibonacci 38.2% 4.2776
Last Price 0.6026
52-Week Low 0.4500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar